Gluegun

Gluegun Therapeutics is a biotechnology company specializing in the discovery and development of next-generation molecular glues for targeted protein degradation. The company leverages a proprietary platform to identify small molecules that induce novel interactions between E3 ubiquitin ligases and disease-causing proteins that were previously considered undruggable. By facilitating the degradation of these targets, Gluegun aims to develop transformative therapies for patients with cancer and other hard-to-treat diseases. The company's approach focuses on expanding the reach of molecular glues beyond traditional targets like IMiDs.